StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently weighed in on the company. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Finally, Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Trading Up 7.2 %

NASDAQ:AGIO opened at $59.06 on Friday. Agios Pharmaceuticals has a 12-month low of $20.40 and a 12-month high of $60.21. The firm has a market cap of $3.37 billion, a PE ratio of 5.20, a price-to-earnings-growth ratio of 0.47 and a beta of 0.75. The stock has a fifty day moving average price of $45.15 and a 200 day moving average price of $42.90.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares in the last quarter. CWM LLC boosted its position in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $216,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.